IN8BIO, INC. filed a Form D with the Securities and Exchange Commission on 2025-12-30.
IN8BIO, INC. filed a Form D notice of an exempt securities offering with the SEC on December 30, 2025. The filing reports $20.12M sold. Its industry group is Biotechnology. It names William Ho (Executive Officer, Director), Patrick McCall (Executive Officer), Alan Roemer (Director) (SEC Form D, December 30, 2025).
Sell to companies like IN8BIO, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-30 · the record
Pitching, partnering or investing alongside them? See who really runs and owns IN8BIO, INC.
Free to see. No signup.
More on the people and the money behind IN8BIO, INC., from the filings we hold.
H.C. Wainwright & Co., LLC received sales compensation on this raise and on 13 other raises we hold, nearest in date first:
Biotechnology raises by companies based in New York, filed in December 2025, largest first.
Get an email when IN8BIO, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when IN8BIO, INC. raises, hires or launches. No email unless you switch it on.
Watch IN8BIO, INC. →Get the full cited report on IN8BIO, INC.
What the filing shows about IN8BIO, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on IN8BIO, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $20.12M, on the same scale — one filing against the whole group's total, so it sits low by construction.
William Ho is named as Executive Officer and Director on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Patrick McCall is named as Executive Officer on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Alan Roemer is named as Director on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Peter Brandt is named as Director on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Emily Fairbairn is named as Director on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Jeremy Graff is named as Director on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Luba Greenwood is named as Director on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Corinne Epperly is named as Director on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Lawrence Lamb is named as Executive Officer on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
Kate Rochlin is named as Executive Officer on the Form D that IN8BIO, INC. filed with the SEC on 30 December 2025, one of 10 people that filing names.
10 people named on the filing — 4 holding an executive role and 6 as directors only.
Named as of the 2025-12-30 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about IN8BIO, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on IN8BIO, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IN8BIO, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist IN8BIO, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind IN8BIO, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for IN8BIO, INC.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in New York
https://mentionfox.com/funding/in8bio-inc-form-d-25000001